EZH2 and Miyoshi myopathy: Data from pre-clinical studies of EZH2 inhibitor E7438 in MM cell lines and mice model showed that EZH2 inhibition causes a global reduction in H3K27me3 methylation in a dose dependent manner, which in turn led to re-expression of tumor suppressor genes in some of the cell lines.